Fig. 4.
![Fig. 4. Hematologic relapse. / Hematologic relapse of CML after BMT using MSD, matched, or partially matched URD in CP1 ([A] n = 369, 1244, 401, respectively;P = .24) and beyond CP (accelerated phase/blast phase; [B] n = 80, 536, 262, respectively; P = .54).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/99/6/10.1182_blood.v99.6.1971/6/h80622296004.jpeg?Expires=1735507942&Signature=NyCJQC8RpMnfml76ZR1aeFS7SXlvoGPWivCUaqedACBn0ottyfwAVqlZj~Y11mHHCoOz0BeTHSv-Tv3HpfSyXRJ~MK7Zx-tMf6qfU2iaoszI4gIhDuJvr60IwYQ~2PVat5O5GHCH9Agf~LVsKXWmufrh-~uhHjs9snxirW897ffAWytSMzca-IRmzahvsclRGnkMbWKLv~hDUFqUVWvfds881AJZZo-JP48UjuStpW4-7ouoLuE~6cP4eQ~kIUgcItLKZ-g0qbZ0M3yxAVnD-u6yilJU8h7CD4zo8tJI3dXimDJGdFwSFj6iiOi3eNxvwpttjZnXubSTbAOfUaaayg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Hematologic relapse.
Hematologic relapse of CML after BMT using MSD, matched, or partially matched URD in CP1 ([A] n = 369, 1244, 401, respectively;P = .24) and beyond CP (accelerated phase/blast phase; [B] n = 80, 536, 262, respectively; P = .54).
